# A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Source: https://onco.cc/trials/nct05627856/  
OnCo record `nct05627856` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GNC-038 in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL is a phase 1/2 interventional study registered as NCT05627856 by Sichuan Baili Pharmaceutical Co., Ltd., with 4 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-038.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05627856
- Phase: 1/2
- Setting: An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 4

## Sources

- ClinicalTrials.gov NCT05627856: https://clinicaltrials.gov/study/NCT05627856

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05627856.json